香港宽频(01310.HK) 宣布，与相达生物科技旗下的家用自测品牌INDICAID妥析达成合作，推出每月自选自我检测产品组合计划，涵盖呼吸道健康、肠胃健康、泌尿生殖或生育健康及癌症风险。
香港宽频客户可按个人需求每月自选INDICAID妥析旗下指定七款自测产品中的任何两盒，进行自我检测，月费48元起，亦可于合约期内加购癌症筛查自测组合，用于检测HPV、幽门螺旋菌及大便隐血等致癌物或预警讯号。
香港宽频业务转型总裁佘隽知表示，近年港人的健康意识渐增，期望透过是次合作，可为全港近百万家庭客户带来价格相宜又便利的医疗保健领域服务。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-11 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.